配伍禁忌中药存在相反之性激其成功的特殊规律，病症条件及配伍环境是影响反药组合毒效表征的关键因素。前期发现附子贝母反药组合具有正性肌力作用并加重心衰是其毒效表现，人参常见于附子反药组合的配伍环境，其如何调控相反相激特性发挥减毒存（增）效的作用值得深入研究。基于此我们提出“增加心肌收缩力、促进心肌细胞凋亡是附子贝母反药组合干预不同病症条件心衰的毒、效表现，人参配伍环境可基于βAR-cAMP-PKA/Epac信号串扰发挥减毒存（增）效的作用”的工作假说。复制肺心病模型，进行附子贝母反药组合对的毒效表征研究，在禁忌条件下考察人参对附子贝母反药组合减毒存（增）效的作用，利用计算化学、分子生物学等方法阐释人参配伍环境对附子贝母反药组合干预心衰减毒存（增）效的化学及生物学基础。为中药配伍减毒存（增）效减研究提供新的思路与方法，为基于相反相激理论创新中药研发提供新的策略。

Incompatibility could stimulate special efficacy when treatment of the disease, the symptom conditions and compatibility environment are key factors on the toxicity and efficacy performance. Our previous study found that Fuzi Beimu incompatibility (FBI) could persistently increase myocardial contractility but aggravate the process of heart failure (HF). Ginseng is commonly used for treatment of heart failure with Fuzi incompatibility. Whether and how Ginseng intervened with FBI to decrease toxicity and keep (or increase) efficacy in treatment of heat failure is worthy to study. Based on the previous study, we propose the hypothesis that “Increasing myocardial contractility and myocardial apoptosis are the toxicity and efficacy of FBI in treatment HF with symptom conditions. Ginseng could decrease toxicity and keep (or increase) efficacy based on βAR-cAMP-PKA/Epac signals crosstalk when FBI treat HF”. Firstly, rat MCT-induced HF models would be employed to determine the contraindication of FBI. The decreasing toxicity and keeping (or increasing) efficacy effects of ginseng combined with FBI in treatment of HF under the contraindication. To clearify the characteristics of ginseng compatibility environment on attenuating toxicity and keeping efficacy. The chemical fundamental and biological mechanism of detoxicity and efficacy saving will be interpreted by using the chemicobiology and molecular biology technology based on cAMP-PKA/Epac signal crosstalk. It will provide a new method of decreasing toxicity and keeping (or increasing) efficacy reaerach of the incompatibility, and provide new strategy for the research and development of new TCM drug based on the “Incompatibility stimulates success” theory.